Overview

A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

Status:
Recruiting
Trial end date:
2026-01-16
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severely active ulcerative colitis.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Janssen Research & Development, LLC
Criteria
Inclusion Criteria:

- Signed informed consent form 18 years of age or older

- Documented diagnosis of ulcerative colitis (UC) of at least 12 weeks prior to
screening

- Moderately to severely active UC as per the modified Mayo score

- Demonstrated inadequate response to or intolerance of conventional therapy and/or
advanced therapy as defined in the protocol

Exclusion Criteria:

- Participants with current or prior diagnosis of fulminant colitis and/or toxic
megacolon

- UC limited to rectum only or to less than (<) 15 centimeters (cm) of colon

- Presence of a stoma

- Presence or history of fistula

- History of extensive colonic resection (example, <30 cm of colon remaining)

- Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, Crohn's
colitis or clinical findings suggestive of Crohn's disease